Xavi Suárez-Calvet

Dr. Xavi Suárez-Calvet

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2012 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LQLuis Querol
Luis Querol
Gisela Nogales-GadeaGisela Nogales-Gadea
Gisela Nogales-Gadea
RRRicard Rojas‐Garcia
Ricard Rojas‐Garcia
EMEugenia Martinez‐Hernandez
Eugenia Martinez‐Hernandez
JDJordi Díaz-Manera
Jordi Díaz-Manera
IIIsabel Illa
Isabel Illa

17 January 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
JDJordi Díaz-Manera
Jordi Díaz-Manera
EME. Martínez-Hernández
E. Martínez-Hernández
LQL. Querol
L. Querol
RKR. Klooster
R. Klooster
RRR. Rojas-García
R. Rojas-García
III. Illa
I. Illa
Objective: Rituximab has emerged as an efficacious option for drug-resistant myasthenia gravis (MG). However, reports published only describe the short-term follow-up of patients treated and little is known about their long-term clinical and immunologic evolution. Our objective was to report the clinical and immunologic long-term follow-up of 17 patients (6 MuSK+MG and 11 AChR+MG) and compare the response between AChR+MG and MuSK+MG patients. Methods: Myasthenia Gravis Foundation America postintervention status and changes in treatment and antibody titers were periodically determined. Lymphocyte subpopulations, total immunoglobulin, immunoglobulin G (IgG) anti-MuSK subclasses, and anti-tetanus toxoid IgG before and after treatment were also studied. Results: After a mean post-treatment period of 31 months, 10 of the AChR+MG patients improved but 6 of them needed reinfusions. In contrast, all MuSK+MG patients achieved a remission (4/6) or minimal manifestations (2/6) status and no reinfusions were needed. Consequently, in the MuSK+MG group, prednisone doses were significantly reduced and concomitant immunosuppressants could be withdrawn. Clinical improvement was associated with a significant decrease in the antibody titers only in the 6 MuSK+MG patients. At last follow-up MuSK antibodies were negative in 3 of these patients and showed a decrease of over 80% in the other 3. Conclusion: In view of the long-lasting benefit observed in MuSK+MG patients, we recommend to use rituximab as an early therapeutic option in this group of patients with MG if they do not respond to prednisone. Classification of evidence: This study provides Class IV evidence that IV rituximab improves the clinical and immunologic status of patients with MuSK+MG.

8 May 2018 in Brain
Verified
Journal Article
Open access
PDF file
LLLeandro Ladislau
Leandro Ladislau
XSXavi Suárez-Calvet
Xavi Suárez-Calvet
STSégolène Toquet
Ségolène Toquet
OLOcéane Landon-Cardinal
Océane Landon-Cardinal
DADamien Amelin
Damien Amelin
YAYves Allenbach
Yves Allenbach
Dermatomyositis is an acquired auto-immune disease characterized by skin lesions and muscle-specific pathological features such as perifascicular muscle fibre atrophy and vasculopathy. Dermatomyositis patients display an upregulation of type I interferon-inducible genes in muscle fibres, endothelial cells, skin and peripheral blood. However, the effect of type I interferon on muscle tissue has not yet been determined. Our aim was to study the pathogenicity of type I interferon in vitro and to evaluate the efficacy of the type I interferon pathway blockade for therapeutic purposes. The activation of type I interferon in differentiating myoblasts abolished myotube formation with reduced myogenin expression while in differentiated myotubes, we observed a reduction in surface area and an upregulation of atrophy-associated genes. In vitro endothelial cells exposure to type I interferon disrupted vascular network organization. All the pathogenic effects observed in vitro were abolished by ruxolitinib. Finally, four refractory dermatomyositis patients were treated with ruxolitinib and improvement ensued in skin lesions, muscle weakness and a reduced serum type I interferon levels and interferon-inducbile genes scores. We propose JAK inhibition as a mechanism-based treatment for dermatomyositis, a finding that is relevant for the design of future clinical trials targeting dermatomyositis.

10 October 2016 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ESEmilia Servián‐Morilla
Emilia Servián‐Morilla
HTHideyuki Takeuchi
Hideyuki Takeuchi
TLTom V Lee
Tom V Lee
JCJordi Clarimon
Jordi Clarimon
FMFabiola Mavillard
Fabiola Mavillard
CPCarmen Paradas
Carmen Paradas
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

6 March 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
XSXavi Suárez-Calvet
Xavi Suárez-Calvet
Eduard GallardoEduard Gallardo
Eduard Gallardo
Gisela Nogales-GadeaGisela Nogales-Gadea
Gisela Nogales-Gadea
LQLuis Querol
Luis Querol
MNMiquel Navas
Miquel Navas
IIIsabel Illa
Isabel Illa

1 March 2016 in The American Journal of Pathology
Verified
Journal Article
Closed access
YAYves Allenbach
Yves Allenbach
GLGaëlle Leroux
Gaëlle Leroux
XSXavi Suárez-Calvet
Xavi Suárez-Calvet
CPCorinna Preusse
Corinna Preusse
Eduard GallardoEduard Gallardo
Eduard Gallardo
FNFrench Myositis Network
French Myositis Network